Thursday, 5 March 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 05 March 2026
News

Back for another tilt at subsidy

Posted 5 March 2026 AM

A Menarini appears steadfast in its attempt to secure subsidy for Orserdu by resubmitting an application to MSAC, suggesting that the oral SERD could land on the PBAC’s July agenda.

While approved by the TGA, Orserdu is not currently listed on the ARTG as the company has decided not to supply the medicine in Australia for the time being, likely due to its high cost. It’s understood to cost more than US$250,000 for a full year of treatment in the US.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (10)

Clinical & Medical, R&D (3)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (16)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.